Radius Health Stock Forecast, Price & News

Radius Health's stock was trading at $16.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RDUS shares have decreased by 16.2% and is now trading at $13.46.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Radius Health.

Radius Health is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Radius Health.

Radius Health will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Radius Health Inc (NASDAQ:RDUS) announced its earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.82) by $0.13. The biopharmaceutical company had revenue of $50.11 million for the quarter, compared to analyst estimates of $48.43 million.
View Radius Health's earnings history.

8 analysts have issued twelve-month price targets for Radius Health's stock. Their forecasts range from $14.00 to $27.00. On average, they anticipate Radius Health's stock price to reach $21.50 in the next twelve months. This suggests a possible upside of 59.7% from the stock's current price.
View analysts' price targets for Radius Health.

Some companies that are related to Radius Health include Axsome Therapeutics (AXSM), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), I-Mab (IMAB), Aimmune Therapeutics (AIMT), Pacira BioSciences (PCRX), Seres Therapeutics (MCRB), Taro Pharmaceutical Industries (TARO), Xencor (XNCR), Karuna Therapeutics (KRTX), Aurinia Pharmaceuticals (AUPH), Madrigal Pharmaceuticals (MDGL), Corcept Therapeutics (CORT), Akcea Therapeutics (AKCA) and Amarin (AMRN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), Opko Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Radius Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.38%), Pacer Advisors Inc. (0.01%) and Valeo Financial Advisors LLC (0.01%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, Target N V Biotech and Willard H Dere.
View institutional ownership trends for Radius Health.

RDUS stock was sold by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC.
View insider buying and selling activity for Radius Health.

RDUS stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., and Pacer Advisors Inc.. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly, and Target N V Biotech.
View insider buying and selling activity for Radius Health.

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RDUS stock can currently be purchased for approximately $13.46.

Radius Health has a market capitalization of $625.51 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe.

The official website for Radius Health is www.radiuspharm.com.

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]